Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-dose esomeprazole-based dual therapy versus standard quadruple therapy for Helicobacter pylori eradication
ChiCTR1900024682Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esomeprazole, furazolidone, amoxicillin, clarithromycin and bismuth subcitrate in Helicobacter pylori infection (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Helicobacter pylori eradication rate. Started Sep 2020; status: recruiting.
02
Drugs
esomeprazolefurazolidoneamoxicillinclarithromycinbismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR1900024682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024682.